Combination of Aromatase Inhibitors with Metronomic Capecitabine: A New Chemoendocrine Treatment for Advanced Breast Cancer

Journals Menu

Follow SCIRP

ISSN Print: 2151-1934
ISSN Online: 2151-1942
www.scirp.org/journal/jct
E-mail: jct@scirp.org

Citations

"Combination of Aromatase Inhibitors with Metronomic Capecitabine: A New Chemoendocrine Treatment for Advanced Breast Cancer"
written by Wei Shi, Xinyue Wang, Xiwen Bi, Wen Xia, Jiajia Huang, Yanhong Su, Zhangzan Huang, Zhongyu Yuan,
published by Journal of Cancer Therapy, Vol.10 No.2, 2019

has been cited by the following article(s):

[1]	Combination of metronomic capecitabine and letrozole in metastatic hormone receptor positive, HER2 negative breast cancer: a randomized phase II trial
	Journal of …, 2024

[2]	Combination of chemotherapy and endocrine treatment in breast cancer—is it still a taboo?
	Oncology in Clinical Practice, 2024

[3]	Assessment of Effectiveness of Maintenance Capecitabine among Triple Negative Breast Cancer Patients Attending Suez Canal University Hospital
	Suez Canal University …, 2023

[4]	Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
	Miranda, FU Lara-Medina… - Current …, 2023

[5]	Mutual exclusivity of ESR1 and TP53 mutations in endocrine resistant metastatic breast cancer
	NPJ Breast …, 2022

[6]	Metronomic chemotherapy combined with endocrine therapy: are we challenging some dogmas?
	2020

[7]	Tratamiento de primera línea del cáncer de mama metastásico hormonosensible con capecitabina e inhibidor de aromatasa
	2019

[8]	Metronomic capecitabine with aromatase inhibitors for patients with metastatic hormone-receptor positive, HER2-negative breast cancer
	2019

[1]	Combination of metronomic capecitabine and letrozole in metastatic hormone receptor positive, HER2 negative breast cancer: a randomized phase II trial Journal of Chemotherapy, 2024 DOI:10.1080/1120009X.2024.2342741

[2]	Chemotherapy Combined With Endocrine Therapy: Old Wine in a New Bottle? Clinical Breast Cancer, 2024 DOI:10.1016/j.clbc.2024.08.018

[3]	Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer Current Oncology, 2023 DOI:10.3390/curroncol30070454

[4]	Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer Current Oncology, 2023 DOI:10.3390/curroncol30070454

[5]	Mutual exclusivity of ESR1 and TP53 mutations in endocrine resistant metastatic breast cancer npj Breast Cancer, 2022 DOI:10.1038/s41523-022-00426-w

[6]	Metronomic chemotherapy combined with endocrine therapy: are we challenging some dogmas? Expert Review of Anticancer Therapy, 2020 DOI:10.1080/14737140.2020.1782200

[7]	Metronomic capecitabine with aromatase inhibitors for patients with metastatic hormone-receptor positive, HER2-negative breast cancer Breast Cancer Management, 2019 DOI:10.2217/bmt-2019-0012

[8]	Metronomic Capecitabine With Aromatase Inhibitors for Patients With Metastatic Hormone-Receptor Positive, HER2-negative Breast Cancer Breast Cancer Management, 2019 DOI:10.2217/bmt-2019-0012

Follow SCIRP